{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Astrocytoma%2C+IDH-Mutant%2C+Grade+3",
    "query": {
      "condition": "Astrocytoma, IDH-Mutant, Grade 3"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T22:56:10.057Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06860594",
      "title": "Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Astrocytoma, IDH-Mutant, Grade 2",
        "Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant",
        "Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant",
        "Recurrent Astrocytoma, IDH-Mutant",
        "Recurrent Astrocytoma, IDH-Mutant, Grade 3",
        "Recurrent Astrocytoma, IDH-Mutant, Grade 4",
        "Recurrent Glioblastoma, IDH-Wildtype"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Triapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-07-30",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-21T22:56:10.057Z",
      "location_count": 42,
      "location_summary": "Duarte, California • Irvine, California • La Jolla, California + 33 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06860594"
    },
    {
      "nct_id": "NCT06815029",
      "title": "Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Astrocytoma, IDH-Mutant, Grade 3",
        "Recurrent Astrocytoma, IDH-Mutant, Grade 4",
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Chimeric Antigen Receptor T-Cell Therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Echocardiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "OTHER"
        },
        {
          "name": "Intracranial Catheter Placement",
          "type": "PROCEDURE"
        },
        {
          "name": "Leukapheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Resection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2025-06-17",
      "completion_date": "2030-10-11",
      "has_results": false,
      "last_update_posted_date": "2025-06-26",
      "last_synced_at": "2026-05-21T22:56:10.057Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06815029"
    },
    {
      "nct_id": "NCT05303519",
      "title": "SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glioma",
        "Astrocytoma, Grade IV",
        "IDH1-mutant Glioma",
        "Astrocytoma, IDH-Mutant, Grade 3",
        "Astrocytoma, IDH-Mutant, Grade 4",
        "Astrocytoma, IDH-Mutant, Grade 2",
        "Oligodendroglioma",
        "Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted"
      ],
      "interventions": [
        {
          "name": "safusidenib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nuvation Bio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 365,
      "start_date": "2023-06-05",
      "completion_date": "2030-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-05-21T22:56:10.057Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05303519"
    },
    {
      "nct_id": "NCT06118723",
      "title": "The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glioblastoma",
        "High-grade Glioma",
        "Glioblastoma, IDH-wildtype",
        "Glioblastoma, IDH-mutant",
        "Glioblastoma Multiforme, Adult",
        "Astrocytoma, Grade IV",
        "Astrocytoma, Grade III",
        "Astrocytoma, Malignant",
        "Brain Neoplasms",
        "Brain Neoplasm, Primary",
        "Brain Neoplasms, Adult",
        "Brain Neoplasm, Malignant"
      ],
      "interventions": [
        {
          "name": "Supramaximal resection",
          "type": "PROCEDURE"
        },
        {
          "name": "Maximal safe resection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Jasper Gerritsen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 784,
      "start_date": "2022-01-01",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2024-02-22",
      "last_synced_at": "2026-05-21T22:56:10.057Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06118723"
    },
    {
      "nct_id": "NCT03180502",
      "title": "Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic Astrocytoma",
        "Anaplastic Oligoastrocytoma",
        "Anaplastic Oligodendroglioma",
        "Diffuse Astrocytoma",
        "Glioma",
        "Oligoastrocytoma",
        "Oligodendroglioma",
        "WHO Grade 3 Glioma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Proton Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "RADIATION",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2018-01-23",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-05-21T22:56:10.057Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Boca Raton, Florida • Miami, Florida + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03180502"
    },
    {
      "nct_id": "NCT03749187",
      "title": "BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "IDH1 Gene Mutation",
        "IDH2 Gene Mutation",
        "Low Grade Glioma",
        "Malignant Glioma",
        "Recurrent Glioblastoma",
        "Recurrent WHO Grade II Glioma",
        "Recurrent WHO Grade III Glioma",
        "WHO Grade II Glioma",
        "WHO Grade III Glioma"
      ],
      "interventions": [
        {
          "name": "PARP Inhibitor BGB-290",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide (TMZ)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "13 Years to 39 Years"
      },
      "enrollment_count": 78,
      "start_date": "2019-04-03",
      "completion_date": "2029-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-05-21T22:56:10.057Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03749187"
    },
    {
      "nct_id": "NCT03528642",
      "title": "Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Astrocytoma, IDH-Mutant, Grade 2",
        "Astrocytoma, IDH-Mutant, Grade 3"
      ],
      "interventions": [
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Telaglenastat Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2019-05-01",
      "completion_date": "2026-09-11",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-21T22:56:10.057Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03528642"
    },
    {
      "nct_id": "NCT05765812",
      "title": "A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype",
        "Astrocytoma, Grade III"
      ],
      "interventions": [
        {
          "name": "Debio 0123",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Debiopharm International SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 116,
      "start_date": "2023-05-15",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-05-21T22:56:10.057Z",
      "location_count": 8,
      "location_summary": "Chicago, Illinois • New York, New York • Dallas, Texas + 4 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05765812"
    },
    {
      "nct_id": "NCT07468136",
      "title": "Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic Oligodendroglioma",
        "Astrocytoma, IDH-Mutant, Grade 3",
        "Astrocytoma, IDH-Mutant, Grade 4",
        "Diffuse Astrocytoma",
        "Glioblastoma, IDH-Wildtype",
        "Malignant Glioma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Eflornithine",
          "type": "DRUG"
        },
        {
          "name": "Lumbar Puncture",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Retifanlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tumor Resection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2026-04-24",
      "completion_date": "2030-10-25",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-05-21T22:56:10.057Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07468136"
    },
    {
      "nct_id": "NCT03434262",
      "title": "SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anaplastic Astrocytoma",
        "Anaplastic Ependymoma",
        "Anaplastic Ganglioglioma",
        "Anaplastic Meningioma",
        "Anaplastic Oligodendroglioma",
        "Pleomorphic Xanthoastrocytoma, Anaplastic",
        "Atypical Teratoid/Rhabdoid Tumor",
        "Brain Cancer",
        "Brain Tumor",
        "Central Nervous System Neoplasms",
        "Choroid Plexus Carcinoma",
        "CNS Embryonal Tumor With Rhabdoid Features",
        "Ganglioneuroblastoma of Central Nervous System",
        "CNS Tumor",
        "Embryonal Tumor of CNS",
        "Ependymoma",
        "Glioblastoma",
        "Glioma",
        "Glioma, Malignant",
        "Medulloblastoma",
        "Medulloblastoma; Unspecified Site",
        "Medulloepithelioma",
        "Neuroepithelial Tumor",
        "Neoplasms",
        "Neoplasms, Neuroepithelial",
        "Papillary Tumor of the Pineal Region (High-grade Only)",
        "Pediatric Brain Tumor",
        "Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)",
        "Pineoblastoma",
        "Primitive Neuroectodermal Tumor",
        "Recurrent Medulloblastoma",
        "Refractory Brain Tumor",
        "Neuroblastoma. CNS",
        "Glioblastoma, IDH-mutant",
        "Glioblastoma, IDH-wildtype",
        "Medulloblastoma, Group 3",
        "Medulloblastoma, Group 4",
        "Glioma, High Grade",
        "Neuroepithelial Tumor, High Grade",
        "Medulloblastoma, SHH-activated and TP53 Mutant",
        "Medulloblastoma, SHH-activated and TP53 Wildtype",
        "Medulloblastoma, Chromosome 9q Loss",
        "Medulloblastoma, Non-WNT Non-SHH, NOS",
        "Medulloblastoma, Non-WNT/Non-SHH",
        "Medulloblastoma, PTCH1 Mutation",
        "Medulloblastoma, WNT-activated",
        "Ependymoma, Recurrent",
        "Glioma, Recurrent High Grade",
        "Glioma, Recurrent Malignant",
        "Embryonal Tumor, NOS",
        "Glioma, Diffuse Midline, H3K27M-mutant",
        "Embryonal Tumor With Multilayered Rosettes (ETMR)",
        "Ependymoma, NOS, WHO Grade III",
        "Ependymoma, NOS, WHO Grade II",
        "Medulloblastoma, G3/G4",
        "Ependymoma, RELA Fusion Positive"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "ribociclib",
          "type": "DRUG"
        },
        {
          "name": "sonidegib",
          "type": "DRUG"
        },
        {
          "name": "trametinib",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "1 Year to 39 Years"
      },
      "enrollment_count": 68,
      "start_date": "2018-03-05",
      "completion_date": "2024-05-24",
      "has_results": false,
      "last_update_posted_date": "2024-05-31",
      "last_synced_at": "2026-05-21T22:56:10.057Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03434262"
    }
  ]
}